Bicara Therapeutics Inc. (NASDAQ:BCAX) Receives Consensus Rating of “Moderate Buy” from Brokerages

Bicara Therapeutics Inc. (NASDAQ:BCAX) has been given an average recommendation of “Moderate Buy” by the nine ratings firms that are currently covering the company, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, seven have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month price objective among brokerages that have updated their coverage on the stock in the last year is $32.43.

BCAX has been the subject of a number of research analyst reports. HC Wainwright reduced their target price on Bicara Therapeutics from $45.00 to $44.00 and set a “buy” rating for the company in a research note on Monday, April 7th. Stifel Nicolaus set a $48.00 target price on shares of Bicara Therapeutics in a research report on Thursday, March 27th. Wedbush reiterated an “outperform” rating and set a $31.00 price target on shares of Bicara Therapeutics in a research report on Thursday, March 27th. Wells Fargo & Company initiated coverage on shares of Bicara Therapeutics in a report on Thursday, April 17th. They issued an “underweight” rating and a $8.00 price objective for the company. Finally, Cantor Fitzgerald reissued an “overweight” rating and set a $13.01 target price on shares of Bicara Therapeutics in a research note on Thursday, March 13th.

Bicara Therapeutics Trading Up 0.5 %

NASDAQ BCAX opened at $14.88 on Wednesday. Bicara Therapeutics has a 52 week low of $8.91 and a 52 week high of $28.09. The company has a 50 day moving average price of $12.84 and a 200 day moving average price of $16.00.

Bicara Therapeutics (NASDAQ:BCAX) last released its quarterly earnings results on Thursday, March 27th. The company reported ($0.39) EPS for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.08). As a group, equities analysts forecast that Bicara Therapeutics will post -2.59 EPS for the current year.

Institutional Investors Weigh In On Bicara Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Red Tree Management LLC purchased a new position in Bicara Therapeutics in the 4th quarter worth approximately $55,230,000. Adage Capital Partners GP L.L.C. increased its stake in shares of Bicara Therapeutics by 171.9% in the 4th quarter. Adage Capital Partners GP L.L.C. now owns 2,175,265 shares of the company’s stock worth $37,893,000 after acquiring an additional 1,375,265 shares during the last quarter. Deep Track Capital LP raised its holdings in shares of Bicara Therapeutics by 151.0% during the 4th quarter. Deep Track Capital LP now owns 2,000,000 shares of the company’s stock worth $34,840,000 after acquiring an additional 1,203,148 shares during the period. Vanguard Group Inc. boosted its position in shares of Bicara Therapeutics by 1,457.9% during the 4th quarter. Vanguard Group Inc. now owns 1,090,528 shares of the company’s stock valued at $18,997,000 after acquiring an additional 1,020,528 shares during the last quarter. Finally, Foresite Capital Management VI LLC purchased a new position in Bicara Therapeutics during the fourth quarter worth about $16,549,000.

Bicara Therapeutics Company Profile

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.